IGHE and allergic disease: Biologic therapy available for other allergic disease treatment, such as anti-IL-5 monoclonal antibodies–mepolizumab, anti-IL-4r blocker dupilumab or omalizumab–anti-IgE monoclonal antibody, were studied in the context of EE treatment, but only dupilumab seems to have sufficient efficacy, while omalizumab and mepolizumab decreased the count of eosinophils in mucosa but did not alleviate symptoms [55,56,57].